About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
JNCE - Jounce Therapeutics| Previous Close | $9.12 | Open | $9.34 |
| Volume | 2.98M | Market Cap | 363.45M |
| Yield | Last Dividend |
| Jounce Therapeutics Reports Third Quarte... | 11/06/20 |
| -On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for??? | |
| Earnings Scheduled For November 6, 2020 | 11/06/20 |
| Companies Reporting Before The Bell ??? Atlantica Sustainable (NASDAQ: AY ) is likely to report quarterly earnings at $0.66 per share on revenue of $2... | |
| Mid-Day Market Update: Superior Industri... | 11/02/20 |
| Midway through trading Monday, the Dow traded up 1.6% to 26,926.47 while the NASDAQ rose 0.36% to 10,950.95. The S&P also rose, gaining 1.23% to ??? | |
| Jounce Therapeutics to Announce Third Qu... | 10/30/20 |
| CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and??? | |
| The Daily Biotech Pulse: Moderna Expands... | 09/16/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeut... | |
| Jounce inks license deal with Gilead val... | 09/01/20 |
| Jounce Therapeutics (NASDAQ:JNCE) enters into an agreement with Gilead Sciences (NASDAQ:GILD) under which the latter will have exclusive global rights... | |
| Jounce Therapeutics Reports Second Quart... | 08/07/20 |
| - Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 ... | |
| Jounce Therapeutics Reports First Quarte... | 05/06/20 |
| ??? Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 ??? ??? Announcing CCR8 as JTX-1811 target; new preclinical data to be prese... | |
| What's in Store for Jounce (JNCE) This E... | 02/20/20 |
| Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results. | |
| Is Jounce Therapeutics (JNCE) Stock Outp... | 12/20/19 |
| Is (JNCE) Outperforming Other Medical Stocks This Year? | |
| Is the Options Market Predicting a Spike... | 12/05/19 |
| Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately. | |
| The Daily Biotech Pulse: Aurinia Rips Hi... | 12/05/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) A... | |
| Jounce Therapeutics, Inc. (JNCE) Reports... | 08/07/19 |
| Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 19.23% and 2.08%, respectively, for the quarter ended June 2019. Do the n... | |
| 2 Promising $5 Biotech Stocks to Conside... | 07/29/19 |
| Jounce Therapeutics (JNCE) and Ocular Therapeutix (OCUL) are two promising biotech stocks selling for less than $5 that each provided investors with p... | |
| What To Know About Jounce's Amended Lice... | 07/24/19 |
| Jounce Therapeutics Inc (NASDAQ: JNCE ) shares are trading higher after the company announced an amended licensing agreement with Celgene Corporation ... | |
| Jounce Therapeutics, Inc. (JNCE) CEO Dr.... | 05/09/19 |
| No summary available. | |
| Peloton IPO: Expects To Start Phase 3 Tr... | 05/09/19 |
| No summary available. | |
| Jounce Therapeutics, Inc. (JNCE) Reports... | 05/08/19 |
| Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -22.58% and -25.55%, respectively, for the quarter ended March 2019. Do t... | |
| Jounce Therapeutics Q1 top line off 2% | 05/08/19 |
| No summary available. | |
| Jounce Therapeutics misses by $0.12, mis... | 05/08/19 |
| Jounce Therapeutics (JNCE): Q1 GAAP EPS of -$0.38 misses by $0.12. Revenue of $10.98M (-2.0% Y/Y) misses by $3.44M. Press Release | |
| Will Jounce Therapeutics, Inc. (JNCE) Re... | 05/01/19 |
| Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. G... | |
| Here's Why Jounce Therapeutics Rose 39.3... | 04/09/19 |
| The biopharma announced full-year 2018 operating results. | |
| Automakers, Macau Names And CinemaCon Ac... | 03/31/19 |
| No summary available. | |
| Seelos Therapeutics and Bio-Path Holding... | 03/12/19 |
| No summary available. | |
| Jounce Therapeutics (JNCE) Investor Pres... | 03/11/19 |
| No summary available. | |
| Jounce Therapeutics (JNCE) CEO Rich Murr... | 03/06/19 |
| No summary available. | |
| Jounce Therapeutics Q4 top line up 55% | 03/06/19 |
| No summary available. | |
| Jounce Therapeutics beats by $0.30, beat... | 03/06/19 |
| No summary available. | |
| Jounce Therapeutics (JNCE) Presents At 3... | 01/10/19 |
| No summary available. | |
| Jounce adds to rally, up 2% | 01/09/19 |
| No summary available. | |
| Buy rating | 12/04/20 |
| and announces Price Target of $11.00 | |
| Buy rating | 11/10/20 |
| Roth Capital maintains Buy rating and lowers Price Target from $28.00 to $15.00 | |
| Date | 2020-11-06 (BMO) | Est. (EPS/Rev.) | ($0.47)/ 2.97M |
| Actual (EPS/Rev.) | $-0.73/ | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| Tech Trades | Tech Trades | 81.00 % | Follow |
| Arbitrage Trade Analytics | Royce Wells | 71.00 % | Subscribe |
| Tech and Biotech Catalysts | Michael | 43.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
